Guggenheim Lifts PT on AtaiBeckley Inc. (ATAI) to $16 From $11

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best stocks under $5 with huge upside potential. Guggenheim lifted the price target on AtaiBeckley Inc. (NASDAQ:ATAI) to $16 from $11 on April 17, maintaining a Buy rating on the shares. The firm told investors that its recent meetings with management reinforced its “conviction” in the BPL-003 program heading into Phase 3 initiation this quarter.

Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds?

In another development, AtaiBeckley Inc. (NASDAQ:ATAI) announced on April 8 peer-reviewed Phase 2a results in CNS Drugs, exhibiting that a single intranasal dose of BPL-003 attained rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression who remained on stable SSRI therapy throughout the study. BPL-003 holds FDA Breakthrough Therapy Designation.

Management reported that A 66.7% antidepressant response rate was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% of participants in the 10 mg cohort and 66.7% of participants in the 12 mg cohort maintaining a response at Week 12.

Headquartered in Germany, AtaiBeckley Inc. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company focused on treating mental health disorders.

While we acknowledge the risk and potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.